Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jie,Ju

第一单位： Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

作者： Jie,Ju ^[1] ; Song-Lin,Gao ^[2] ; Jia-Yu,Wang ^[1] ; Die,Sang ^[3] ; Yi-Kun,Kang ^[4] ; Xue,Wang ^[5] ; Jian,Yue ^[5] ; You,Shuai ^[1] ; Yi-Xin,Qi ^[6] ; Peng,Yuan ^[5]

作者单位： Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ^[1] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute, Beijing, China. ^[2] Department of Medical Oncology, Beijing Sanhuan Cancer Hospital, Beijing, China. ^[3] Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. ^[4] Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ^[5] Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shi Jiazhuang, China. ^[6]

关键词 breast cancer hormone receptor human epidermal growth factor receptor 2 ovarian function suppression trastuzumab

主题词人类(Humans);成年人(Adult);女(雌)性(Female);乳腺肿瘤(Breast Neoplasms);随访研究(Follow-Up Studies);预后(Prognosis);托瑞米芬(Toremifene);回顾性研究(Retrospective Studies);他莫昔芬(Tamoxifen);无病生存(Disease-Free Survival);化学疗法, 辅助(Chemotherapy, Adjuvant)

DOI 10.1111/1759-7714.15211

PMID 38185807

发布时间 2024-02-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Thoracic cancer

2024年15卷6期

439-447页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.

Thoracic cancer

相似文献

Thoracic cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.

Thoracic cancer

相似文献

Thoracic cancer

相关期刊

检索历史清除